Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy.
Publication/Presentation Date
6-1-2021
Abstract
Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.
Volume
13
Issue
6
First Page
15805
Last Page
15805
ISSN
2168-8184
Published In/Presented At
Li, S., Sharma, N., Kazmierski, D., Amjad, M. A., Dong, Y., Wang, Y., Sharma, N., Ramakrishna, S., & Ochieng, P. (2021). Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy. Cureus, 13(6), e15805. https://doi.org/10.7759/cureus.15805
Disciplines
Medicine and Health Sciences
PubMedID
34306873
Department(s)
Department of Medicine
Document Type
Article